… biotechnology or pharmaceutical industry, with a proven leadership role in clinical development or related functions, … clinical sites, patient organizations, and CROs. Excellent leadership, communication, strategic thinking, and analytical … experience representing clinical programs to internal leadership, external experts, and regulatory bodies. …
… As Principal Scientist Liver , you will provide scientific leadership for our liver programs, driving the discovery and … and non-scientific stakeholders, including senior leadership. We expect our Principal Scientist Liver to have: …
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr.
